ZA200307956B - Use of osteopontin for the treatment and/or prevention of neurologic diseases. - Google Patents

Info

Publication number

ZA200307956B

ZA200307956B ZA200307956A ZA200307956A ZA200307956B ZA 200307956 B ZA200307956 B ZA 200307956B ZA 200307956 A ZA200307956 A ZA 200307956A ZA 200307956 A ZA200307956 A ZA 200307956A ZA 200307956 B ZA200307956 B ZA 200307956B

Authority

ZA

South Africa

Prior art keywords

osteopontin

use according

amino acid

disease

sequences

Prior art date

2001-05-17

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004264 Osteopontin Human genes 0.000 title claims description 247
• 108010081689 Osteopontin Proteins 0.000 title claims description 247
• 238000011282 treatment Methods 0.000 title claims description 81
• 208000012902 Nervous system disease Diseases 0.000 title claims description 49
• 230000002265 prevention Effects 0.000 title claims description 20
• 108090000623 proteins and genes Proteins 0.000 claims description 142
• 102000004169 proteins and genes Human genes 0.000 claims description 72
• 201000006417 multiple sclerosis Diseases 0.000 claims description 67
• 208000016192 Demyelinating disease Diseases 0.000 claims description 59
• 210000003169 central nervous system Anatomy 0.000 claims description 54
• 230000000694 effects Effects 0.000 claims description 54
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 39
• 229920001184 polypeptide Polymers 0.000 claims description 36
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
• 150000001413 amino acids Chemical class 0.000 claims description 33
• 102000014150 Interferons Human genes 0.000 claims description 32
• 108010050904 Interferons Proteins 0.000 claims description 32
• 208000006011 Stroke Diseases 0.000 claims description 30
• 201000001119 neuropathy Diseases 0.000 claims description 27
• 230000007823 neuropathy Effects 0.000 claims description 27
• 150000003839 salts Chemical class 0.000 claims description 27
• 230000037396 body weight Effects 0.000 claims description 22
• 108010029485 Protein Isoforms Proteins 0.000 claims description 19
• 102000001708 Protein Isoforms Human genes 0.000 claims description 19
• 229940079322 interferon Drugs 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 18
• 238000004519 manufacturing process Methods 0.000 claims description 18
• 150000007523 nucleic acids Chemical class 0.000 claims description 18
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 18
• 102000039446 nucleic acids Human genes 0.000 claims description 15
• 108020004707 nucleic acids Proteins 0.000 claims description 15
• 239000000556 agonist Substances 0.000 claims description 14
• 239000013598 vector Substances 0.000 claims description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
• 230000008499 blood brain barrier function Effects 0.000 claims description 12
• 210000001218 blood-brain barrier Anatomy 0.000 claims description 12
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
• 208000018737 Parkinson disease Diseases 0.000 claims description 11
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
• 208000028389 Nerve injury Diseases 0.000 claims description 10
• 230000008764 nerve damage Effects 0.000 claims description 10
• 230000004770 neurodegeneration Effects 0.000 claims description 10
• 208000024827 Alzheimer disease Diseases 0.000 claims description 9
• 208000023105 Huntington disease Diseases 0.000 claims description 9
• 238000006467 substitution reaction Methods 0.000 claims description 9
• 230000000472 traumatic effect Effects 0.000 claims description 9
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
• 208000016245 inborn errors of metabolism Diseases 0.000 claims description 7
• 230000000295 complement effect Effects 0.000 claims description 6
• 239000013604 expression vector Substances 0.000 claims description 6
• 108060003951 Immunoglobulin Proteins 0.000 claims description 5
• 102000018358 immunoglobulin Human genes 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 230000004927 fusion Effects 0.000 claims description 4
• 230000001939 inductive effect Effects 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 230000002708 enhancing effect Effects 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 238000001415 gene therapy Methods 0.000 claims description 2
• 208000017787 Paraneoplastic neurologic syndrome Diseases 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 150
• 210000004556 brain Anatomy 0.000 description 100
• 210000004248 oligodendroglia Anatomy 0.000 description 100
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 77
• 230000014509 gene expression Effects 0.000 description 77
• 210000005036 nerve Anatomy 0.000 description 73
• 235000018102 proteins Nutrition 0.000 description 68
• 230000006378 damage Effects 0.000 description 62
• 101000613820 Homo sapiens Osteopontin Proteins 0.000 description 57
• 102100040557 Osteopontin Human genes 0.000 description 55
• 238000000034 method Methods 0.000 description 54
• DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 52
• 108010083674 Myelin Proteins Proteins 0.000 description 45
• 102000006386 Myelin Proteins Human genes 0.000 description 45
• 210000005012 myelin Anatomy 0.000 description 44
• 201000010099 disease Diseases 0.000 description 41
• 241001465754 Metazoa Species 0.000 description 40
• 208000014674 injury Diseases 0.000 description 39
• 206010012305 Demyelination Diseases 0.000 description 38
• 241000699670 Mus sp. Species 0.000 description 38
• 241000699666 Mus <mouse, genus> Species 0.000 description 36
• 238000004458 analytical method Methods 0.000 description 36
• 210000003050 axon Anatomy 0.000 description 36
• 208000035475 disorder Diseases 0.000 description 36
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
• 239000000523 sample Substances 0.000 description 32
• 239000003981 vehicle Substances 0.000 description 32
• 235000001014 amino acid Nutrition 0.000 description 31
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
• 230000023105 myelination Effects 0.000 description 27
• 208000027418 Wounds and injury Diseases 0.000 description 26
• 239000000835 fiber Substances 0.000 description 26
• 210000003205 muscle Anatomy 0.000 description 25
• 239000002243 precursor Substances 0.000 description 25
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 24
• 238000006243 chemical reaction Methods 0.000 description 24
• 239000002299 complementary DNA Substances 0.000 description 23
• 230000035755 proliferation Effects 0.000 description 23
• 210000001519 tissue Anatomy 0.000 description 23
• 239000012634 fragment Substances 0.000 description 22
• 230000006870 function Effects 0.000 description 22
• 230000003902 lesion Effects 0.000 description 22
• 230000008569 process Effects 0.000 description 22
• 210000000278 spinal cord Anatomy 0.000 description 22
• 238000007920 subcutaneous administration Methods 0.000 description 22
• 238000000338 in vitro Methods 0.000 description 21
• 210000001428 peripheral nervous system Anatomy 0.000 description 21
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
• 108020004999 messenger RNA Proteins 0.000 description 20
• 210000002569 neuron Anatomy 0.000 description 20
• 241000282414 Homo sapiens Species 0.000 description 19
• 150000001875 compounds Chemical class 0.000 description 19
• 230000008929 regeneration Effects 0.000 description 19
• 238000011069 regeneration method Methods 0.000 description 19
• 208000024891 symptom Diseases 0.000 description 19
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 18
• 102100040019 Interferon alpha-1/13 Human genes 0.000 description 18
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 18
• 206010033799 Paralysis Diseases 0.000 description 18
• 206010036105 Polyneuropathy Diseases 0.000 description 18
• 230000007824 polyneuropathy Effects 0.000 description 18
• 239000000243 solution Substances 0.000 description 18
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 17
• 108020004414 DNA Proteins 0.000 description 17
• 108090000467 Interferon-beta Proteins 0.000 description 17
• 239000002609 medium Substances 0.000 description 17
• 210000003007 myelin sheath Anatomy 0.000 description 17
• 102000003996 Interferon-beta Human genes 0.000 description 16
• 230000033228 biological regulation Effects 0.000 description 16
• 230000004069 differentiation Effects 0.000 description 16
• 201000005518 mononeuropathy Diseases 0.000 description 16
• 239000013641 positive control Substances 0.000 description 16
• 238000011084 recovery Methods 0.000 description 16
• 230000003376 axonal effect Effects 0.000 description 15
• 230000001684 chronic effect Effects 0.000 description 15
• 230000003210 demyelinating effect Effects 0.000 description 15
• 230000009274 differential gene expression Effects 0.000 description 15
• 230000001965 increasing effect Effects 0.000 description 15
• 238000011534 incubation Methods 0.000 description 15
• 230000002757 inflammatory effect Effects 0.000 description 15
• 239000000203 mixture Substances 0.000 description 15
• 238000003556 assay Methods 0.000 description 14
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 14
• -1 DNA or RNA Chemical class 0.000 description 13
• 208000002193 Pain Diseases 0.000 description 13
• 230000001154 acute effect Effects 0.000 description 13
• 230000000875 corresponding effect Effects 0.000 description 13
• 230000007423 decrease Effects 0.000 description 13
• 235000005911 diet Nutrition 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• 229960001388 interferon-beta Drugs 0.000 description 13
• 229940047124 interferons Drugs 0.000 description 13
• 102000005962 receptors Human genes 0.000 description 13
• 108020003175 receptors Proteins 0.000 description 13
• 230000008733 trauma Effects 0.000 description 13
• 241000700159 Rattus Species 0.000 description 12
• AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 12
• 230000004071 biological effect Effects 0.000 description 12
• 230000001054 cortical effect Effects 0.000 description 12
• 230000018109 developmental process Effects 0.000 description 12
• 206010012601 diabetes mellitus Diseases 0.000 description 12
• 230000037213 diet Effects 0.000 description 12
• 238000002493 microarray Methods 0.000 description 12
• 230000036407 pain Effects 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 230000004083 survival effect Effects 0.000 description 12
• 208000011580 syndromic disease Diseases 0.000 description 12
• 241000701447 unidentified baculovirus Species 0.000 description 12
• 208000008457 Neurologic Manifestations Diseases 0.000 description 11
• 125000000539 amino acid group Chemical group 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 238000011161 development Methods 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 230000001953 sensory effect Effects 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 230000003827 upregulation Effects 0.000 description 11
• 102000004127 Cytokines Human genes 0.000 description 10
• 108090000695 Cytokines Proteins 0.000 description 10
• 238000001061 Dunnett's test Methods 0.000 description 10
• 102000004877 Insulin Human genes 0.000 description 10
• 108090001061 Insulin Proteins 0.000 description 10
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
• 206010040030 Sensory loss Diseases 0.000 description 10
• 210000001744 T-lymphocyte Anatomy 0.000 description 10
• 210000001367 artery Anatomy 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
• 208000015181 infectious disease Diseases 0.000 description 10
• 229940125396 insulin Drugs 0.000 description 10
• 210000002540 macrophage Anatomy 0.000 description 10
• 238000005259 measurement Methods 0.000 description 10
• 230000001105 regulatory effect Effects 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• 102100034343 Integrase Human genes 0.000 description 9
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
• 230000036982 action potential Effects 0.000 description 9
• 239000000872 buffer Substances 0.000 description 9
• 230000034994 death Effects 0.000 description 9
• 230000007850 degeneration Effects 0.000 description 9
• 208000028867 ischemia Diseases 0.000 description 9
• 230000033001 locomotion Effects 0.000 description 9
• 239000000463 material Substances 0.000 description 9
• 238000011002 quantification Methods 0.000 description 9
• 230000008439 repair process Effects 0.000 description 9
• 238000011160 research Methods 0.000 description 9
• 241000894007 species Species 0.000 description 9
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
• 206010028980 Neoplasm Diseases 0.000 description 8
• 238000000636 Northern blotting Methods 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 8
• 230000009286 beneficial effect Effects 0.000 description 8
• 230000017531 blood circulation Effects 0.000 description 8
• 208000029028 brain injury Diseases 0.000 description 8
• CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 8
• 229960005263 bucladesine Drugs 0.000 description 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
• 238000009396 hybridization Methods 0.000 description 8
• 230000008595 infiltration Effects 0.000 description 8
• 238000001764 infiltration Methods 0.000 description 8
• 230000007246 mechanism Effects 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 230000001537 neural effect Effects 0.000 description 8
• 230000007971 neurological deficit Effects 0.000 description 8
• 230000002981 neuropathic effect Effects 0.000 description 8
• 239000012188 paraffin wax Substances 0.000 description 8
• 230000000750 progressive effect Effects 0.000 description 8
• 210000003497 sciatic nerve Anatomy 0.000 description 8
• 208000032843 Hemorrhage Diseases 0.000 description 7
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
• 241000190070 Sarracenia purpurea Species 0.000 description 7
• 208000007536 Thrombosis Diseases 0.000 description 7
• 208000030886 Traumatic Brain injury Diseases 0.000 description 7
• 210000001130 astrocyte Anatomy 0.000 description 7
• 238000004364 calculation method Methods 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 230000002354 daily effect Effects 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 238000010606 normalization Methods 0.000 description 7
• 239000013612 plasmid Substances 0.000 description 7
• 235000008160 pyridoxine Nutrition 0.000 description 7
• 239000011677 pyridoxine Substances 0.000 description 7
• 238000006722 reduction reaction Methods 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 229940011671 vitamin b6 Drugs 0.000 description 7
• 210000004885 white matter Anatomy 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 6
• 206010012289 Dementia Diseases 0.000 description 6
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 210000005013 brain tissue Anatomy 0.000 description 6
• 210000004899 c-terminal region Anatomy 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 210000001638 cerebellum Anatomy 0.000 description 6
• 238000007906 compression Methods 0.000 description 6
• 230000006835 compression Effects 0.000 description 6
• 239000000499 gel Substances 0.000 description 6
• 210000002414 leg Anatomy 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 210000000274 microglia Anatomy 0.000 description 6
• 208000035824 paresthesia Diseases 0.000 description 6
• 230000004224 protection Effects 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 238000010839 reverse transcription Methods 0.000 description 6
• 230000035807 sensation Effects 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 210000003625 skull Anatomy 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 210000002435 tendon Anatomy 0.000 description 6
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 5
• 206010010071 Coma Diseases 0.000 description 5
• 208000005189 Embolism Diseases 0.000 description 5
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
• 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 5
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
• 108010005716 Interferon beta-1a Proteins 0.000 description 5
• 208000016604 Lyme disease Diseases 0.000 description 5
• 241001529936 Murinae Species 0.000 description 5
• 101000613819 Mus musculus Osteopontin Proteins 0.000 description 5
• 206010028289 Muscle atrophy Diseases 0.000 description 5
• 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 5
• 102000013275 Somatomedins Human genes 0.000 description 5
• LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 5
• 238000000540 analysis of variance Methods 0.000 description 5
• 230000000840 anti-viral effect Effects 0.000 description 5
• 230000037444 atrophy Effects 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 210000001124 body fluid Anatomy 0.000 description 5
• 239000010839 body fluid Substances 0.000 description 5
• 208000026106 cerebrovascular disease Diseases 0.000 description 5
• 210000000877 corpus callosum Anatomy 0.000 description 5
• 239000003599 detergent Substances 0.000 description 5
• 206010013023 diphtheria Diseases 0.000 description 5
• 229960003638 dopamine Drugs 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 210000001320 hippocampus Anatomy 0.000 description 5
• 230000004054 inflammatory process Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 208000030159 metabolic disease Diseases 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 238000007491 morphometric analysis Methods 0.000 description 5
• 201000000585 muscular atrophy Diseases 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 230000007830 nerve conduction Effects 0.000 description 5
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
• 230000002093 peripheral effect Effects 0.000 description 5
• 230000011514 reflex Effects 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• 208000030507 AIDS Diseases 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• 206010002091 Anaesthesia Diseases 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 208000037157 Azotemia Diseases 0.000 description 4
• 206010048962 Brain oedema Diseases 0.000 description 4
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 4
• 208000018652 Closed Head injury Diseases 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 206010019196 Head injury Diseases 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 208000028226 Krabbe disease Diseases 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 206010024229 Leprosy Diseases 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• 239000007993 MOPS buffer Substances 0.000 description 4
• 208000001089 Multiple system atrophy Diseases 0.000 description 4
• 102000014413 Neuregulin Human genes 0.000 description 4
• 108050003475 Neuregulin Proteins 0.000 description 4
• 206010034701 Peroneal nerve palsy Diseases 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 108091000054 Prion Proteins 0.000 description 4
• 239000013614 RNA sample Substances 0.000 description 4
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 208000036142 Viral infection Diseases 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000036770 blood supply Effects 0.000 description 4
• 230000006931 brain damage Effects 0.000 description 4
• 231100000874 brain damage Toxicity 0.000 description 4
• 208000006752 brain edema Diseases 0.000 description 4
• 230000003925 brain function Effects 0.000 description 4
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 4
• 238000001516 cell proliferation assay Methods 0.000 description 4
• 230000002490 cerebral effect Effects 0.000 description 4
• 238000012790 confirmation Methods 0.000 description 4
• 239000010949 copper Substances 0.000 description 4
• 210000003792 cranial nerve Anatomy 0.000 description 4
• 238000012258 culturing Methods 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 230000006866 deterioration Effects 0.000 description 4
• 230000003828 downregulation Effects 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 210000002950 fibroblast Anatomy 0.000 description 4
• 210000003811 finger Anatomy 0.000 description 4
• 210000002683 foot Anatomy 0.000 description 4
• 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 description 4
• 208000010726 hind limb paralysis Diseases 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007928 intraperitoneal injection Substances 0.000 description 4
• 208000036546 leukodystrophy Diseases 0.000 description 4
• 230000005012 migration Effects 0.000 description 4
• 230000000877 morphologic effect Effects 0.000 description 4
• 230000003387 muscular Effects 0.000 description 4
• 210000001577 neostriatum Anatomy 0.000 description 4
• 210000004498 neuroglial cell Anatomy 0.000 description 4
• 230000007658 neurological function Effects 0.000 description 4
• 230000016273 neuron death Effects 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 125000003729 nucleotide group Chemical group 0.000 description 4
• 210000001328 optic nerve Anatomy 0.000 description 4
• 208000021090 palsy Diseases 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 210000000578 peripheral nerve Anatomy 0.000 description 4
• 230000026731 phosphorylation Effects 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• 239000004033 plastic Substances 0.000 description 4
• 229920003023 plastic Polymers 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 230000002035 prolonged effect Effects 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
• 210000004116 schwann cell Anatomy 0.000 description 4
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
• 210000002027 skeletal muscle Anatomy 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 231100000167 toxic agent Toxicity 0.000 description 4
• 230000002588 toxic effect Effects 0.000 description 4
• 239000003440 toxic substance Substances 0.000 description 4
• 208000009852 uremia Diseases 0.000 description 4
• 230000001457 vasomotor Effects 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• ZBCATMYQYDCTIZ-UHFFFAOYSA-N 4-methylcatechol Chemical compound CC1=CC=C(O)C(O)=C1 ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 description 3
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 3
• IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
• 206010003694 Atrophy Diseases 0.000 description 3
• 206010008132 Cerebral thrombosis Diseases 0.000 description 3
• 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 3
• 108020004635 Complementary DNA Proteins 0.000 description 3
• 208000034656 Contusions Diseases 0.000 description 3
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 108010042681 Galactosylceramidase Proteins 0.000 description 3
• 206010021143 Hypoxia Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 3
• 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 3
• 208000010428 Muscle Weakness Diseases 0.000 description 3
• 206010028372 Muscular weakness Diseases 0.000 description 3
• 102000002423 Octamer Transcription Factor-6 Human genes 0.000 description 3
• 108010068113 Octamer Transcription Factor-6 Proteins 0.000 description 3
• 206010033892 Paraplegia Diseases 0.000 description 3
• 206010034010 Parkinsonism Diseases 0.000 description 3
• 108010081690 Pertussis Toxin Proteins 0.000 description 3
• 108091000080 Phosphotransferase Proteins 0.000 description 3
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
• 241000097929 Porphyria Species 0.000 description 3
• 208000010642 Porphyrias Diseases 0.000 description 3
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
• 108091034057 RNA (poly(A)) Proteins 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 3
• 102000004338 Transferrin Human genes 0.000 description 3
• 108090000901 Transferrin Proteins 0.000 description 3
• 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 3
• 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 206010002022 amyloidosis Diseases 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 210000000612 antigen-presenting cell Anatomy 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000001363 autoimmune Effects 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 230000002146 bilateral effect Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 230000000740 bleeding effect Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 210000004958 brain cell Anatomy 0.000 description 3
• 210000000133 brain stem Anatomy 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 208000010877 cognitive disease Diseases 0.000 description 3
• 239000003636 conditioned culture medium Substances 0.000 description 3
• 239000000356 contaminant Substances 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 235000020188 drinking water Nutrition 0.000 description 3
• 239000003651 drinking water Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 230000002518 glial effect Effects 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 235000003642 hunger Nutrition 0.000 description 3
• 208000034783 hypoesthesia Diseases 0.000 description 3
• 208000003532 hypothyroidism Diseases 0.000 description 3
• 230000002989 hypothyroidism Effects 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 238000010874 in vitro model Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 102000006495 integrins Human genes 0.000 description 3
• 108010044426 integrins Proteins 0.000 description 3
• 229960004461 interferon beta-1a Drugs 0.000 description 3
• 230000035987 intoxication Effects 0.000 description 3
• 231100000566 intoxication Toxicity 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• 230000007775 late Effects 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 230000003340 mental effect Effects 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 231100000862 numbness Toxicity 0.000 description 3
• 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 230000000399 orthopedic effect Effects 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229960001412 pentobarbital Drugs 0.000 description 3
• 102000020233 phosphotransferase Human genes 0.000 description 3
• 208000000813 polyradiculoneuropathy Diseases 0.000 description 3
• 230000008092 positive effect Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 210000004129 prosencephalon Anatomy 0.000 description 3
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 3
• 208000009873 radial neuropathy Diseases 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 210000000273 spinal nerve root Anatomy 0.000 description 3
• 230000037351 starvation Effects 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 239000012581 transferrin Substances 0.000 description 3
• 230000001052 transient effect Effects 0.000 description 3
• 230000009529 traumatic brain injury Effects 0.000 description 3
• 238000002255 vaccination Methods 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 210000000707 wrist Anatomy 0.000 description 3
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
• MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 2
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
• FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
• 208000018126 Adrenomyeloneuropathy Diseases 0.000 description 2
• 102100034452 Alternative prion protein Human genes 0.000 description 2
• 206010001939 Aminoaciduria Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003399 Arthropod bite Diseases 0.000 description 2
• FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 2
• 238000000035 BCA protein assay Methods 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 208000010392 Bone Fractures Diseases 0.000 description 2
• 208000002381 Brain Hypoxia Diseases 0.000 description 2
• 208000024806 Brain atrophy Diseases 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 206010008190 Cerebrovascular accident Diseases 0.000 description 2
• 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 description 2
• 206010069729 Collateral circulation Diseases 0.000 description 2
• OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 2
• YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical group SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 2
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 206010017076 Fracture Diseases 0.000 description 2
• 102100028496 Galactocerebrosidase Human genes 0.000 description 2
• 208000015872 Gaucher disease Diseases 0.000 description 2
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000703512 Homo sapiens Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 2
• 208000004044 Hypesthesia Diseases 0.000 description 2
• 206010021639 Incontinence Diseases 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 101710085938 Matrix protein Proteins 0.000 description 2
• 101710127721 Membrane protein Proteins 0.000 description 2
• 208000027382 Mental deterioration Diseases 0.000 description 2
• 206010027374 Mental impairment Diseases 0.000 description 2
• ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 2
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
• 208000021642 Muscular disease Diseases 0.000 description 2
• 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 2
• 102100032965 Myomesin-2 Human genes 0.000 description 2
• OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 102000007072 Nerve Growth Factors Human genes 0.000 description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
• 208000003019 Neurofibromatosis 1 Diseases 0.000 description 2
• 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 2
• 208000014060 Niemann-Pick disease Diseases 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 101150057744 PDGFA gene Proteins 0.000 description 2
• 208000027089 Parkinsonian disease Diseases 0.000 description 2
• 201000011252 Phenylketonuria Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 102000029797 Prion Human genes 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 239000005700 Putrescine Substances 0.000 description 2
• 206010037751 Radial nerve palsy Diseases 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
• 208000034189 Sclerosis Diseases 0.000 description 2
• 206010039966 Senile dementia Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 208000029033 Spinal Cord disease Diseases 0.000 description 2
• 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 2
• 208000022292 Tay-Sachs disease Diseases 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 241000710209 Theiler's encephalomyelitis virus Species 0.000 description 2
• DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 2
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
• 208000004374 Tick Bites Diseases 0.000 description 2
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
• NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 description 2
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
• 208000003443 Unconsciousness Diseases 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 208000003056 Vitamin B6 deficiency Diseases 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
• 229960004373 acetylcholine Drugs 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000004931 aggregating effect Effects 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 238000001949 anaesthesia Methods 0.000 description 2
• 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
• 108010068380 arginylarginine Proteins 0.000 description 2
• 125000003435 aroyl group Chemical group 0.000 description 2
• 230000001174 ascending effect Effects 0.000 description 2
• 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• 230000010442 axonal sprouting Effects 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 125000001589 carboacyl group Chemical group 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 230000009850 completed effect Effects 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 230000009519 contusion Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 108010004073 cysteinylcysteine Proteins 0.000 description 2
• 229960000860 dapsone Drugs 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000003203 everyday effect Effects 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 230000003492 excitotoxic effect Effects 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 230000004438 eyesight Effects 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 210000000245 forearm Anatomy 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 230000005021 gait Effects 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 125000003827 glycol group Chemical group 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 239000001046 green dye Substances 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 229910001385 heavy metal Inorganic materials 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 102000051312 human SPP1 Human genes 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 230000007574 infarction Effects 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 229960003350 isoniazid Drugs 0.000 description 2
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 230000002045 lasting effect Effects 0.000 description 2
• 201000010901 lateral sclerosis Diseases 0.000 description 2
• 210000005240 left ventricle Anatomy 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 230000005923 long-lasting effect Effects 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 108010054155 lysyllysine Proteins 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 108010085203 methionylmethionine Proteins 0.000 description 2
• 238000010208 microarray analysis Methods 0.000 description 2
• 230000002025 microglial effect Effects 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000009456 molecular mechanism Effects 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000002161 motor neuron Anatomy 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 201000005545 motor peripheral neuropathy Diseases 0.000 description 2
• 208000018731 motor weakness Diseases 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 206010065579 multifocal motor neuropathy Diseases 0.000 description 2
• 210000004126 nerve fiber Anatomy 0.000 description 2
• 210000001178 neural stem cell Anatomy 0.000 description 2
• 230000009251 neurologic dysfunction Effects 0.000 description 2
• 230000002232 neuromuscular Effects 0.000 description 2
• 239000002858 neurotransmitter agent Substances 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 235000018343 nutrient deficiency Nutrition 0.000 description 2
• 230000003565 oculomotor Effects 0.000 description 2
• 239000002751 oligonucleotide probe Substances 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 235000006408 oxalic acid Nutrition 0.000 description 2
• 208000010713 partial hind limb paralysis Diseases 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 230000007542 postnatal development Effects 0.000 description 2
• 150000003141 primary amines Chemical class 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 229960004919 procaine Drugs 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000000272 proprioceptive effect Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000002731 protein assay Methods 0.000 description 2
• 238000003753 real-time PCR Methods 0.000 description 2
• 229940038850 rebif Drugs 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 150000003335 secondary amines Chemical class 0.000 description 2
• 230000036362 sensorimotor function Effects 0.000 description 2
• 230000007958 sleep Effects 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 239000011781 sodium selenite Substances 0.000 description 2
• 229960001471 sodium selenite Drugs 0.000 description 2
• 235000015921 sodium selenite Nutrition 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 210000003594 spinal ganglia Anatomy 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 210000003813 thumb Anatomy 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 231100000563 toxic property Toxicity 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• 230000001228 trophic effect Effects 0.000 description 2
• 108010045269 tryptophyltryptophan Proteins 0.000 description 2
• 210000001364 upper extremity Anatomy 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• 150000003751 zinc Chemical class 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• JWXPYNYNEUYKOW-JTQLQIEISA-N (2s)-n-(4-nitrophenyl)pyrrolidine-2-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)[C@H]1NCCC1 JWXPYNYNEUYKOW-JTQLQIEISA-N 0.000 description 1
• RGNVSYKVCGAEHK-GUBZILKMSA-N (3s)-3-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical group NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O RGNVSYKVCGAEHK-GUBZILKMSA-N 0.000 description 1
• LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• 101150084750 1 gene Proteins 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• 101150098072 20 gene Proteins 0.000 description 1
• 229940124321 AIDS medicine Drugs 0.000 description 1
• 102000003678 AMPA Receptors Human genes 0.000 description 1
• 108090000078 AMPA Receptors Proteins 0.000 description 1
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
• 102100021580 Active regulator of SIRT1 Human genes 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
• WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 244000291564 Allium cepa Species 0.000 description 1
• 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• 206010059313 Anogenital warts Diseases 0.000 description 1
• 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
• BNODVYXZAAXSHW-IUCAKERBSA-N Arg-His Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BNODVYXZAAXSHW-IUCAKERBSA-N 0.000 description 1
• RJUHZPRQRQLCFL-IMJSIDKUSA-N Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O RJUHZPRQRQLCFL-IMJSIDKUSA-N 0.000 description 1
• HZYFHQOWCFUSOV-IMJSIDKUSA-N Asn-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O HZYFHQOWCFUSOV-IMJSIDKUSA-N 0.000 description 1
• CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101000613814 Bos taurus Osteopontin Proteins 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 208000004434 Calcinosis Diseases 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000238097 Callinectes sapidus Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000005403 Casein Kinases Human genes 0.000 description 1
• 108010031425 Casein Kinases Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 208000014912 Central Nervous System Infections Diseases 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 description 1
• 201000006868 Charcot-Marie-Tooth disease type 3 Diseases 0.000 description 1
• GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
• 241000272194 Ciconiiformes Species 0.000 description 1
• 208000010200 Cockayne syndrome Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 208000000907 Condylomata Acuminata Diseases 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• 208000019736 Cranial nerve disease Diseases 0.000 description 1
• VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• DSTWKJOBKSMVCV-UWVGGRQHSA-N Cys-Tyr Chemical group SC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DSTWKJOBKSMVCV-UWVGGRQHSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
• 208000000202 Diffuse Axonal Injury Diseases 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 206010066054 Dysmorphism Diseases 0.000 description 1
• 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 1
• 101150066038 E4 gene Proteins 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 description 1
• 208000025127 Erdheim-Chester disease Diseases 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 241000483002 Euproctis similis Species 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 208000034347 Faecal incontinence Diseases 0.000 description 1
• 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 208000015220 Febrile disease Diseases 0.000 description 1
• 206010061159 Foot deformity Diseases 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 206010017577 Gait disturbance Diseases 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
• 206010061431 Glial scar Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 1
• CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
• VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
• 208000023329 Gun shot wound Diseases 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 208000000013 Hammer Toe Syndrome Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• VHOLZZKNEBBHTH-YUMQZZPRSA-N His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 VHOLZZKNEBBHTH-YUMQZZPRSA-N 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
• 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 description 1
• 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 1
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
• 101000626165 Homo sapiens Putative tenascin-XA Proteins 0.000 description 1
• 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
• 208000005420 Hyperemesis Gravidarum Diseases 0.000 description 1
• 206010021135 Hypovitaminosis Diseases 0.000 description 1
• 241000899793 Hypsophrys nicaraguensis Species 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
• 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 208000025069 Juvenile Huntington disease Diseases 0.000 description 1
• VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
• 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
• 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 238000012313 Kruskal-Wallis test Methods 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 241000322338 Loeseliastrum Species 0.000 description 1
• 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
• LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 102100025136 Macrosialin Human genes 0.000 description 1
• 239000004425 Makrolon Substances 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• HGCNKOLVKRAVHD-RYUDHWBXSA-N Met-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-RYUDHWBXSA-N 0.000 description 1
• 108020005196 Mitochondrial DNA Proteins 0.000 description 1
• 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
• 206010027940 Mood altered Diseases 0.000 description 1
• 206010072927 Mucolipidosis type I Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 108010079364 N-glycylalanine Proteins 0.000 description 1
• 208000013233 NARP syndrome Diseases 0.000 description 1
• 208000006079 Near drowning Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 102400000058 Neuregulin-1 Human genes 0.000 description 1
• 108090000556 Neuregulin-1 Proteins 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 208000011644 Neurologic Gait disease Diseases 0.000 description 1
• 206010029326 Neuropathic arthropathy Diseases 0.000 description 1
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010031127 Orthostatic hypotension Diseases 0.000 description 1
• 206010031252 Osteomyelitis Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 238000002944 PCR assay Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010053869 POEMS syndrome Diseases 0.000 description 1
• 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
• 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 206010033885 Paraparesis Diseases 0.000 description 1
• 208000002774 Paraproteinemias Diseases 0.000 description 1
• 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
• 208000020547 Peroxisomal disease Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• PYOHODCEOHCZBM-RYUDHWBXSA-N Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 PYOHODCEOHCZBM-RYUDHWBXSA-N 0.000 description 1
• GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 1
• JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 229920000805 Polyaspartic acid Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 208000004210 Pressure Ulcer Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
• RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 101710092489 Protein kinase 2 Proteins 0.000 description 1
• 102100024653 Putative tenascin-XA Human genes 0.000 description 1
• 206010037714 Quadriplegia Diseases 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 101150026963 RPS19BP1 gene Proteins 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 238000010240 RT-PCR analysis Methods 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 101001121466 Rattus norvegicus Osteopontin Proteins 0.000 description 1
• 101000703459 Rattus norvegicus Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 241000219100 Rhamnaceae Species 0.000 description 1
• 206010039203 Road traffic accident Diseases 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 208000013608 Salla disease Diseases 0.000 description 1
• 208000008039 Secondary Parkinson Disease Diseases 0.000 description 1
• 206010040021 Sensory abnormalities Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 1
• 102000007365 Sialoglycoproteins Human genes 0.000 description 1
• 108010032838 Sialoglycoproteins Proteins 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 108010052164 Sodium Channels Proteins 0.000 description 1
• 102000018674 Sodium Channels Human genes 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 208000002548 Spastic Paraparesis Diseases 0.000 description 1
• 208000020339 Spinal injury Diseases 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 208000010513 Stupor Diseases 0.000 description 1
• 229920006328 Styrofoam Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 206010043647 Thrombotic Stroke Diseases 0.000 description 1
• 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• BVZABQIRMYTKCF-JSGCOSHPSA-N Trp-Met Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(O)=O)=CNC2=C1 BVZABQIRMYTKCF-JSGCOSHPSA-N 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 238000010162 Tukey test Methods 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
• BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 1
• JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010059790 Ulnar nerve palsy Diseases 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• 206010065441 Venous haemorrhage Diseases 0.000 description 1
• 102000013127 Vimentin Human genes 0.000 description 1
• 108010065472 Vimentin Proteins 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
• 206010073696 Wallerian degeneration Diseases 0.000 description 1
• 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
• 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 description 1
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000004308 accommodation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 210000001642 activated microglia Anatomy 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 108010047495 alanylglycine Proteins 0.000 description 1
• 108010087924 alanylproline Proteins 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940030225 antihemorrhagics Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 108010038633 aspartylglutamate Proteins 0.000 description 1
• 101150117004 atg18 gene Proteins 0.000 description 1
• 230000006470 autoimmune attack Effects 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 230000032846 axon ensheathment Effects 0.000 description 1
• 230000007844 axonal damage Effects 0.000 description 1
• 230000007845 axonopathy Effects 0.000 description 1
• 210000001142 back Anatomy 0.000 description 1
• 229960002319 barbital Drugs 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 238000010009 beating Methods 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 208000002894 beriberi Diseases 0.000 description 1
• DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
• GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 239000003181 biological factor Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 238000010241 blood sampling Methods 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 230000008468 bone growth Effects 0.000 description 1
• 230000018678 bone mineralization Effects 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 230000001612 cachectic effect Effects 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000001269 cardiogenic effect Effects 0.000 description 1
• 210000001715 carotid artery Anatomy 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 230000006999 cognitive decline Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000005056 compaction Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 210000001653 corpus striatum Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 238000009223 counseling Methods 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 108010069495 cysteinyltyrosine Proteins 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 238000011157 data evaluation Methods 0.000 description 1
• 230000032459 dedifferentiation Effects 0.000 description 1
• 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
• 210000001787 dendrite Anatomy 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 229960002656 didanosine Drugs 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 230000009521 diffuse axonal injury Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000012137 double-staining Methods 0.000 description 1
• 238000002567 electromyography Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 230000001712 encephalitogenic effect Effects 0.000 description 1
• 208000030172 endocrine system disease Diseases 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 239000003257 excitatory amino acid Substances 0.000 description 1
• 230000002461 excitatory amino acid Effects 0.000 description 1
• 231100000318 excitotoxic Toxicity 0.000 description 1
• 231100000063 excitotoxicity Toxicity 0.000 description 1
• 201000010934 exostosis Diseases 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000001917 fluorescence detection Methods 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 239000012595 freezing medium Substances 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
• 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
• 238000010413 gardening Methods 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000006589 gland dysfunction Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
• YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
• 229940076085 gold Drugs 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 230000000025 haemostatic effect Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
• 229960004068 hexachlorophene Drugs 0.000 description 1
• UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
• 229960002456 hexobarbital Drugs 0.000 description 1
• 108010028295 histidylhistidine Proteins 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 210000002758 humerus Anatomy 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 201000010930 hyperostosis Diseases 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000009413 insulation Methods 0.000 description 1
• 230000003933 intellectual function Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 238000012332 laboratory investigation Methods 0.000 description 1
• 210000003140 lateral ventricle Anatomy 0.000 description 1
• 229950008325 levothyroxine Drugs 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 108010009298 lysylglutamic acid Proteins 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 210000001617 median nerve Anatomy 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 230000008172 membrane trafficking Effects 0.000 description 1
• 230000006609 metabolic stress Effects 0.000 description 1
• 210000001872 metatarsal bone Anatomy 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• 108010068488 methionylphenylalanine Proteins 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 208000012268 mitochondrial disease Diseases 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 230000007510 mood change Effects 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 210000002894 multi-fate stem cell Anatomy 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000004898 n-terminal fragment Anatomy 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000008035 nerve activity Effects 0.000 description 1
• 230000001722 neurochemical effect Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 230000005015 neuronal process Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
• 229960000564 nitrofurantoin Drugs 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
• 210000000956 olfactory bulb Anatomy 0.000 description 1
• 206010030875 ophthalmoplegia Diseases 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000033116 oxidation-reduction process Effects 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 230000008058 pain sensation Effects 0.000 description 1
• 229940055726 pantothenic acid Drugs 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 1
• 229960000989 perhexiline Drugs 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 230000002572 peristaltic effect Effects 0.000 description 1
• 201000011197 peroneal nerve paralysis Diseases 0.000 description 1
• 208000031232 peroneal neuropathy Diseases 0.000 description 1
• 239000000575 pesticide Substances 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000008180 pharmaceutical surfactant Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
• 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000008055 phosphate buffer solution Substances 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 108010055896 polyornithine Proteins 0.000 description 1
• 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 235000020004 porter Nutrition 0.000 description 1
• 230000002516 postimmunization Effects 0.000 description 1
• 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 230000036544 posture Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
• 210000002248 primary sensory neuron Anatomy 0.000 description 1
• REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
• 229960000244 procainamide Drugs 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 208000026526 progressive weakness Diseases 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 108010077112 prolyl-proline Proteins 0.000 description 1
• 108010029020 prolylglycine Proteins 0.000 description 1
• 230000009023 proprioceptive sensation Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 210000002637 putamen Anatomy 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000011897 real-time detection Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 239000013643 reference control Substances 0.000 description 1
• 230000021298 regulation of T cell migration Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000008263 repair mechanism Effects 0.000 description 1
• 230000002336 repolarization Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 210000004189 reticular formation Anatomy 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 210000005245 right atrium Anatomy 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000003118 sandwich ELISA Methods 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
• 239000013049 sediment Substances 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 238000010008 shearing Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000008261 styrofoam Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
• 229960005314 suramin Drugs 0.000 description 1
• 238000001847 surface plasmon resonance imaging Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229910052714 tellurium Inorganic materials 0.000 description 1
• PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• 229950003937 tolonium Drugs 0.000 description 1
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000031998 transcytosis Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000007723 transport mechanism Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229940035722 triiodothyronine Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 108010003137 tyrosyltyrosine Proteins 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 210000000658 ulnar nerve Anatomy 0.000 description 1
• 208000036722 ulnar neuropathy Diseases 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 210000005048 vimentin Anatomy 0.000 description 1
• 210000000605 viral structure Anatomy 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 208000030401 vitamin deficiency disease Diseases 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 230000001755 vocal effect Effects 0.000 description 1
• 230000008734 wallerian degeneration Effects 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 230000037303 wrinkles Effects 0.000 description 1
• NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1
• OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
• 229960002791 zimeldine Drugs 0.000 description 1
• 229910000166 zirconium phosphate Inorganic materials 0.000 description 1